FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091034300> ?p ?o ?g. }

• W2091034300 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCTumor cells can induce RANKL expression in the bone stroma, causing activation of osteoclasts which consequently mediate bone breakdown and subsequent tumor proliferation. RANKL is an essential mediator of osteoclast function and survival. RANKL inhibition by OPG-Fc can prevent tumor-induced osteolysis, decrease skeletal tumor burden, and increase survival in preclinical models. Denosumab is an anti-huRANKL antibody approved for the prevention of skeletal-related events due to bone metastases from solid tumors. Selective anti-huRANKL antibodies do not bind murine RANKL, therefore efficacy cannot be tested in typical mouse models. We developed a breast cancer bone metastasis model in mice in which exon 5 from murine RANKL was replaced with its human ortholog (“mu/huRANKL”). We tested the effect of AMG 161, an antibody which binds huRANKL and chimeric mu/huRANKL, on tumor burden and associated osteoclasts. After intra-cardiac injection of MCF-7Luc breast carcinoma cells, hind limb metastases formed and tumor burden was tracked by bioluminescence imaging (BLI). AMG 161 (0.3 or 3.0 mg/kg, 2x/week), OPG-Fc (3.0 mg/kg, 2x/week) or vehicle were administered beginning 10 days post tumor injection to treat established bone metastases until study termination at day 31. AMG 161 resulted in a dose-dependent decrease in skeletal tumor burden (3.0 mg/kg: 84% decrease vs. control p=0.0052) similar to that observed with OPG-Fc (85% decrease vs. control, p=0.0038). Histological analysis at the end of the study showed reductions in skeletal tumor burden consistent with the BLI. AMG 161 treatment resulted in a significant decrease in tumor-associated osteoclasts (TRAP staining) and inhibition of osteolytic lesions (X-ray). The inhibition of tumor burden by the anti-RANKL antibody was indirect via osteoclast inhibition since MCF-7Luc cells do not express RANK, and RANKL inhibition does not affect subcutaneous growth of MCF-7Luc cells. These data support the efficacy of anti-RANKL antibody treatment to inhibit tumor-induced osteoclastogenesis and to block the growth of bone metastases.Citation Format: Jude R. Canon, Rebecca Bryant, Martine Roudier, William C. Dougall. AMG 161, a fully human monoclonal antibody to human RANKL, inhibits tumor-induced osteoclastogenesis and reduces skeletal tumor burden in mice that express chimeric (murine / human) RANKL. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3947. doi:10.1158/1538-7445.AM2013-3947" @default.
• W2091034300 created "2016-06-24" @default.
• W2091034300 creator A5016057308 @default.
• W2091034300 creator A5035364268 @default.
• W2091034300 creator A5044848608 @default.
• W2091034300 creator A5063849736 @default.
• W2091034300 date "2013-04-15" @default.
• W2091034300 modified "2023-09-26" @default.
• W2091034300 title "Abstract 3947: AMG 161, a fully human monoclonal antibody to human RANKL, inhibits tumor-induced osteoclastogenesis and reduces skeletal tumor burden in mice that express chimeric (murine / human) RANKL." @default.
• W2091034300 doi "https://doi.org/10.1158/1538-7445.am2013-3947" @default.
• W2091034300 hasPublicationYear "2013" @default.
• W2091034300 type Work @default.
• W2091034300 sameAs 2091034300 @default.
• W2091034300 citedByCount "1" @default.
• W2091034300 countsByYear W20910343002017 @default.
• W2091034300 crossrefType "proceedings-article" @default.
• W2091034300 hasAuthorship W2091034300A5016057308 @default.
• W2091034300 hasAuthorship W2091034300A5035364268 @default.
• W2091034300 hasAuthorship W2091034300A5044848608 @default.
• W2091034300 hasAuthorship W2091034300A5063849736 @default.
• W2091034300 hasConcept C121608353 @default.
• W2091034300 hasConcept C126322002 @default.
• W2091034300 hasConcept C141071460 @default.
• W2091034300 hasConcept C142724271 @default.
• W2091034300 hasConcept C159654299 @default.
• W2091034300 hasConcept C170493617 @default.
• W2091034300 hasConcept C203014093 @default.
• W2091034300 hasConcept C2776033226 @default.
• W2091034300 hasConcept C2776107976 @default.
• W2091034300 hasConcept C2776286101 @default.
• W2091034300 hasConcept C2776541429 @default.
• W2091034300 hasConcept C2777783956 @default.
• W2091034300 hasConcept C2779013556 @default.
• W2091034300 hasConcept C2779428903 @default.
• W2091034300 hasConcept C2781282405 @default.
• W2091034300 hasConcept C502942594 @default.
• W2091034300 hasConcept C71924100 @default.
• W2091034300 hasConcept C88045685 @default.
• W2091034300 hasConceptScore W2091034300C121608353 @default.
• W2091034300 hasConceptScore W2091034300C126322002 @default.
• W2091034300 hasConceptScore W2091034300C141071460 @default.
• W2091034300 hasConceptScore W2091034300C142724271 @default.
• W2091034300 hasConceptScore W2091034300C159654299 @default.
• W2091034300 hasConceptScore W2091034300C170493617 @default.
• W2091034300 hasConceptScore W2091034300C203014093 @default.
• W2091034300 hasConceptScore W2091034300C2776033226 @default.
• W2091034300 hasConceptScore W2091034300C2776107976 @default.
• W2091034300 hasConceptScore W2091034300C2776286101 @default.
• W2091034300 hasConceptScore W2091034300C2776541429 @default.
• W2091034300 hasConceptScore W2091034300C2777783956 @default.
• W2091034300 hasConceptScore W2091034300C2779013556 @default.
• W2091034300 hasConceptScore W2091034300C2779428903 @default.
• W2091034300 hasConceptScore W2091034300C2781282405 @default.
• W2091034300 hasConceptScore W2091034300C502942594 @default.
• W2091034300 hasConceptScore W2091034300C71924100 @default.
• W2091034300 hasConceptScore W2091034300C88045685 @default.
• W2091034300 hasLocation W20910343001 @default.
• W2091034300 hasOpenAccess W2091034300 @default.
• W2091034300 hasPrimaryLocation W20910343001 @default.
• W2091034300 hasRelatedWork W1976836551 @default.
• W2091034300 hasRelatedWork W2000200224 @default.
• W2091034300 hasRelatedWork W2026564867 @default.
• W2091034300 hasRelatedWork W2034274846 @default.
• W2091034300 hasRelatedWork W2066935669 @default.
• W2091034300 hasRelatedWork W2072211701 @default.
• W2091034300 hasRelatedWork W2089775635 @default.
• W2091034300 hasRelatedWork W2112523271 @default.
• W2091034300 hasRelatedWork W2125553683 @default.
• W2091034300 hasRelatedWork W2197623271 @default.
• W2091034300 hasRelatedWork W2261624644 @default.
• W2091034300 hasRelatedWork W2325703190 @default.
• W2091034300 hasRelatedWork W2329754083 @default.
• W2091034300 hasRelatedWork W2531522165 @default.
• W2091034300 hasRelatedWork W2581516071 @default.
• W2091034300 hasRelatedWork W2768195183 @default.
• W2091034300 hasRelatedWork W2790263126 @default.
• W2091034300 hasRelatedWork W2791751767 @default.
• W2091034300 hasRelatedWork W2794179488 @default.
• W2091034300 hasRelatedWork W3032233855 @default.
• W2091034300 isParatext "false" @default.
• W2091034300 isRetracted "false" @default.
• W2091034300 magId "2091034300" @default.
• W2091034300 workType "article" @default.